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Abstract
Introduction: Elevated serum levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFa) correlate
with an increased risk for atherothrombotic events and TNFa is known to induce prothrombotic molecules in
endothelial cells. Based on the preexisting evidence for the impact of TNFa in the pathogenesis of autoimmune
disorders and their known association with an acquired hypercoagulability, we investigated the effects of TNFa
and the role of the TNF receptor subtypes TNFR1 and TNFR2 for arteriolar thrombosis in vivo.
Methods: Arteriolar thrombosis and platelet-rolling in vivo were investigated in wildtype, TNFR1-/-, TNFR2-/- and
TNFR1-/R2-/- C57BL/6 mice using intravital microscopy in the dorsal skinfold chamber microcirculation model. In
vitro, expression of prothrombotic molecules was assessed in human endothelial cells by real-time PCR and flow
cytometry.
Results: In wildtype mice, stimulation with TNFa significantly accelerated thrombotic vessel occlusion in vivo upon
ferric chloride injury. Arteriolar thrombosis was much more pronounced in TNFR1-/- animals, where TNFa
additionally led to increased platelet-endothelium-interaction. TNFa dependent prothrombotic effects were not
observed in TNFR2-/- and TNFR1-/R2- mice. In vitro, stimulation of human platelet rich plasma with TNFa did not
influence aggregation properties. In human endothelial cells, TNFa induced superoxide production, p-selectin,
tissue factor and PAI-1, and suppressed thrombomodulin, resulting in an accelerated endothelial dependent blood
clotting in vitro. Additionally, TNFa caused the release of soluble mediators by endothelial cells which induced
prothrombotic and suppressed anticoagulant genes comparable to direct TNFa effects.
Conclusions: TNFa accelerates thrombus formation in an in vivo model of arteriolar thrombosis. Its prothrombotic
effects in vivo require TNFR2 and are partly compensated by TNFR1. In vitro studies indicate endothelial
mechanisms to be responsible for prothrombotic TNFa effects. Our results support a more selective therapeutic
approach in anticytokine therapy favouring TNFR2 specific antagonists.
Introduction
Tumor necrosis factor alpha (TNFa) is known to exert
pleiotropic effects on the host defense which fundamen-
tally differ depending on an acute or chronic release, the
occurrence of a disequilibrium between pro- and anti-
inflammatory mediators, and the concomitant regulation
of other cytokines sharing certain biological properties.
Trimeric TNFa acts by binding to one of the TNFa
receptors (TNFRs): TNFR1 or TNFR2 [1,2]. Whereas
TNFR1 is widely expressed, expression of TNFR2 is
found mainly on immune and endothelial cells [3,4]. The
receptors have different affinity for the soluble and the
membrane-bound forms of TNFa (transmembrane
TNFa, or tmTNFa); TNFR1 binds the two forms equally
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well, whereas TNFR2 has a higher affinity for tmTNFa.
Both receptor subtypes are associated with the activation
of nuclear factor-kappa-B (NF-B). However, the signal-
ing pathways are complex and partly crosslinked, and
TNFa is able to induce cell death as well as proliferation,
differentiation, and migration [5].
The impact of TNFa in the pathogenesis of autoim-
mune disorders such as systemic lupus erythematosus and
rheumatoid arthritis (RA) has been widely accepted [6].
TNFa is known to mediate synovial cell proliferation and
bone resorption in RA [7] as well as activation of endothe-
lial cells and fibroblast chemotaxis in systemic sclerosis
[8]. In patients with systemic lupus erythematosus, high
serum levels of TNFa correlating with disease activity
have been described, and its role in the development of
lupus nephritis is accepted [9]. Additionally, patients
affected by RA are at increased risk for cardiovascular
morbidity and atherothrombotic events not ascribable to
traditional risk factors [10-12]. Not only is atherosclerosis
considered to be an inflammatory process with increased
serum levels of TNFa present in patients with athero-
thrombotic diseases [13,14], but TNFa has been associated
directly to endothelial dysfunction by mediating NF-B
translocation, increasing production of reactive oxygen
species, and affecting endothelial nitric oxide synthase
expression [15-17]. In addition, systemic inflammation
implicates prothrombotic conditions by upregulation of
procoagulant factors, downregulation of natural anticoagu-
lants, and inhibition of fibrinolysis. More specifically,
TNFa induces the expression of tissue factor and sup-
presses thrombomodulin as well as the endothelial cell
protein C receptor [18,19]. Hence, an acquired hypercoa-
gulability is frequently associated with autoimmune disor-
ders. Finally, platelets represent a further important link
between inflammation, atherogenesis, and thrombosis
[20,21].
An effective blockade of TNFa-dependent cytokine cas-
cades and leukocyte recruitment as well as good clinical
and serological response rates have led to the establish-
ment of therapy with TNFa inhibitors in RA and other
autoimmune disorders. Reduction of atherosclerotic com-
plications relating to attenuation of the acute-phase
response, including C-reactive protein, platelet count, and
fibrinogen, has been reported [22]. In light of the occur-
rence of serious side effects, though, the use of a non-
selective blockade of all TNFa effects has been questioned.
In this study, we used the dorsal skinfold chamber
microcirculatory model for in vivo assessment of arteriolar
thrombosis and platelet-vessel wall interaction (PVWI) to
investigate whether TNFa increases arteriolar thrombus
formation in vivo, define the underlying platelet- or




Murine TNFa was from Chemicon International (now part
of Millipore Corporation, Billerica, MA, USA), human
TNFa was from ReliaTech (Wolfenbüttel, Germany),
collagen was from Nycomed (now part of Takeda Pharma-
ceuticals International, Zürich, Switzerland), and anti-
human tissue factor-FITC, anti-human P-selectin-RPE, and
respective negative controls were from AbD Serotec
(Oxford, UK). RNeasy Mini Kit, small interfering RNA
(siRNA) against TNFR1 and TNFR2, and Effectene trans-
fection kit were from Qiagen (Hilden, Germany), and pre-
designed glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), TNFR1, TNFR2, plasminogen activator inhibi-
tor 1 (PAI-1), tissue factor, and thrombomudulin TaqMan
primers were from Applied Biosystems (Foster City, CA,
USA). All other chemicals were from Sigma-Aldrich
(Munich, Germany).
Animals
Animal experiments were performed in wild-type (WT) or
TNFa receptor-deficient C57BL/6 mice. WT mice were
purchased from Charles River (Sulzfeld, Germany).
TNFR1−/− and TNFR2−/− mice were originally obtained
from the Jackson Laboratory (Bar Harbor, ME, USA), and
TNFR1−/−R2−/− mice were subsequently generated by
cross-breeding. Surgical procedures were performed under
short-term anesthesia induced by a single intraperitoneal
injection of midazolam 3 mg/kg (Ratiopharm, Ulm,
Germany), fentanyl 0.03 mg/kg (CuraMED Pharma,
Baden-Württemberg, Germany), and medetomidinhy-
drochloride 0.3 mg/kg (Pfizer, Berlin, Germany; produced
by Orion Pharma, Espoo, Finland) diluted in 0.9% NaCl.
After the experiments, the animals were killed by injection
of an overdose (2 g/kg) of sodium pentobarbital (Merial,
Hallbergmoos, Germany). All experiments were conducted
in accordance with the German animal protection law and
approved by the district government of Upper Bavaria
(approval reference number AZ 55.2-1-54-2531-162-08).
The investigation conforms to Directive 2010/63/EU of
the European Parliament.
Intravital microscopy in the dorsal skinfold chamber
microcirculatory model
The dorsal skinfold chamber microcirculatory model was
used in mice as described previously [23]. Animals with
an intact microcirculation underwent carotid artery
catheterization for application of drugs or injection of
isolated platelets, respectively. Intravital fluorescence
microscopy was performed by using a modified micro-
scope (Zeiss Axiotech Vario; Carl Zeiss, Oberkochen,
Germany). Images were recorded with a digital camera
(AxioCam HSm; Carl Zeiss). For all in vivo experiments,
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TNFa was administered via carotid artery catheter at a
dose of 0.4 µg/kg. This was calculated to match plasma
levels of approximately 5 ng/mL, which caused effects in
vitro.
Intravital assessment of arteriolar thrombosis
Intravital thrombotic vessel occlusion time was assessed
in arterioles of WT or TNFa receptor-deficient C57BL/6
mice in the dorsal skinfold chamber model. For induction
of intra-arteriolar thrombosis, the ferric chloride superfu-
sion method was used as described previously [23,24].
Before the experiments, blood vessel flow was digitally
recorded and regular blood flow was confirmed for all
analyzed arterioles. To visualize vessel lumina before ves-
sel injury, 50 µL of a 5% fluorescein isothiocyanate-
labeled dextran solution (FITC-dextran, molecular weight
150,000) was infused via the carotid catheter. Injury to
the vascular wall was then performed by application of
30 µL of a ferric chloride solution (25 mmol/L) onto
arterioles by using a standardized protocol, and movies
were recorded until blood flow ceased.
Mouse platelet isolation and staining for in vivo studies
Whole blood was drawn from anesthetized mice by car-
diac puncture. To prevent blood from clotting, syringes
contained 10% of sodium citrate. The citrated whole blood
was spun at 130g, and the obtained platelet-rich plasma
(PRP) was incubated with carboxyfluorescin (carboxyfluor-
escein diacetate succinimidyl ester 17 µmol/L; Bachem,
Bubendorf, Switzerland) in the dark for 30 minutes.
Labeled platelets were then spun at 340g and resuspended
in a buffered calcium-free physiologic solution (138
mmol/L NaCl, 2.7 mmol/L KCl, 12 mmol/L NaHCO3,
0.4 mmol/L NaH2PO4, 1 mmol/L MgCl2 × 6 H2O,
5 mmol/L D-glucose, 5 mmol/L Hepes; pH 7.35). For cen-
trifugation, iloprost (10 ng/mL; Schering, Berlin-Wedding,
Germany) was added to prevent platelet activation. The
ability of the isolated and stained platelets to aggregate
was tested by platelet aggregometry.
Intravital analysis of platelet-vessel wall interaction
For intravital studies of platelet interaction with the intact
vessel wall, isolated and fluorescent-stained murine plate-
lets from a donor animal were injected via a carotid artery
catheter and observed in the dorsal skinfold chamber
model. Movie sequences of 30 seconds in four- to six-
vessel segments in each animal were recorded and ana-
lyzed by using AxioVision Software (Carl Zeiss). Vessels
with abnormal flow were excluded from analysis. From
the resulting length of the platelet trace in single images,
velocities of single platelets were calculated by using the
exposure time of each single picture. PVWI was expressed
in frequency histograms consisting of all platelet velocities
analyzed. Histograms were normalized to the maximum
platelet speed within a vessel to exclude biasing influences
of altered blood flow velocities between different arterioles.
As a consequence, a rightward shift in platelet velocity dis-
tribution within a histogram expresses less PVWI, whereas
a leftward shift signalizes increased PVWI at the arteriolar
wall. Platelets with less than 5% of the velocity of the fast-
est platelets were defined as rolling platelets.
Aggregation studies
Platelet aggregation was measured by using the turbidi-
metric method described by Born [25]. Human or murine
PRP was obtained by centrifugation (130g) of whole
citrated blood drawn from human cubital veins or by car-
diac puncture in mice. ADP-, collagen-, or thrombin
receptor-activating peptide (TRAP)-induced platelet
aggregation was measured photometrically by using a two-
channel aggregometer (ChronoLog 490-2D; Chrono-log
Corporation, Havertown, PA, USA) under continuous stir-
ring at 1,000 revolutions per minute at 37°C. Written con-
sent was obtained from platelet donors. To assess the
effects of endothelial-derived cytokines, 100 µL of super-
natant of stimulated human microvascular endothelial
cells (HMECs) was added to 300 µL of PRP and incubated
for 90 minutes before agonist-induced aggregation was
measured.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
isolated and cultured as described previously [26]. The
procedure was approved by a university ethics review
board. HMECs were provided by Ades and colleagues [27]
and cultured in M199 media supplemented with 10% fetal
calf serum, 10% endothelial growth media (PromoCell,
Heidelberg, Germany), and 1% penicillin/streptomycin.
The investigation conforms to the principles outlined in
the Declaration of Helsinki.
Measurement of endothelial superoxide (O2
-)
For superoxide measurements, the cytochrome c reduc-
tion method was used as previously described [28]. The
O2
--dependent part of cytochrome c reduction was calcu-
lated from the difference in absorbance (550 nm)
between samples incubated with or without superoxide
dismutase.
Endothelial surface molecule expression
HMECs or HUVECs were grown as described and incu-
bated with sham or TNFa (5 ng/mL) as indicated. Cells
were stained by using anti-p-selectin-RPE and anti-tissue
factor-FITC or corresponding RPE- or FITC-labeled
negative control. For measuring, a FACSCanto II flow
cytometer (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA) was used. Data were analyzed by using
FACSDiva software (Becton, Dickinson and Company).
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Real-time polymerase chain reaction in endothelial cells
HMECs were incubated with sham or TNFa for indicated
time points. RNA isolation and real-time polymerase chain
reaction (PCR) were performed as described previously
[29]. Commercially available pre-developed TaqMan
reagents were used for the human target genes thrombo-
modulin, PAI-1, tissue factor, TNFR1, and TNFR2, and
GAPDH was used as a reference housekeeping gene. All
measurements were performed in duplicates.
Endothelial-dependent blood clotting
Cells were stimulated with TNFa as indicated and then
lysed with 15 mM n-octyl-D-glycopyranosidase in 0.1 M
imidazol buffer; 20 μL of cell lysate and 20 μL of
200 mmol/L CaCl2 for re-calcification were added to
300 μL of citrated (3.13% sodium citrate) human whole
blood from healthy volunteers, and clotting time was mea-
sured by thrombelastometry (Rotem; Tem Innovations,
Munich, Germany). Stimulation with human recombinant
tissue factor was used as a positive control.
Role of autocrine factors
To assess the role of TNFa-induced autocrine factors
released by endothelial cells, cells were stimulated with
TNFa 5 ng/mL for 3 hours. After removal of the TNFa-
containing medium and a washing step, fresh medium
without TNFa was added to the cells to allow secretion
of prothrombotic factors. After 2 hours, this medium was
used to stimulate untreated cells in which several para-
meters then were measured.
Small interfering RNA knockdown
Endothelial cells were transfected with 50 nM siRNA
against human TNFR1 and TNFR2 by using the magneto-
fection method in combination with the Effectene kit from
Qiagen as previously described [30]. Transfected cells
were left 48 hours to allow siRNA-mediated knockdown,
which was confirmed by real-time PCR and Western blot,
which was performed as described elsewhere [30].
Statistical analysis
SigmaStat Software (SYSTAT, Chicago, IL, USA) was used
to calculate statistical differences. Data were analyzed by
using Student t test for normally distributed variables or
the Mann-Whitney rank sum test, when normal distribu-
tion was not given. Data are expressed as mean ± standard
error of the mean. Differences were considered significant
when the error probability level was a P value of less than
0.05.
Results
Arteriolar thrombus formation in vivo
To analyze the effect of TNFa on thrombus formation
in vivo, we assessed the time to thrombotic arteriolar
vessel occlusion following injury by ferric chloride
superfusion to the vascular wall. The time to complete
thrombotic vessel occlusion upon injury was signifi-
cantly accelerated from 260 ± 31 seconds in control ani-
mals to 158 ± 31 seconds in animals treated with TNFa
over a period of 4 hours prior to the experiment (n = 8,
P <0.05 versus control animals). Vessel occlusion time
was not significantly accelerated compared with control
animals when TNFa was given only half an hour prior
to the experiment (241 ± 54 seconds; n = 5; Figure 1a).
To investigate the contribution of signaling via the
TNFa receptor subtypes, we measured time to thrombo-
tic vessel occlusion in TNFR1−/−, TNFR2−/−, and
TNFR1-/R2−/− mice. The ability of TNFa to accelerate
arteriolar thrombus formation in vivo observed in WT
mice (Figure 1a) was further enhanced in TNFR1−/−
mice, in which the mean vessel occlusion time after treat-
ment with TNFa was reduced to 62 ± 13 seconds (n = 5,
P < 0.05 versus sham-treated TNFR1−/−; Figure 2a), cor-
responding to a TNFa-dependent relative acceleration of
thrombotic vessel occlusion time of 37% ± 12% in WT
mice and of 71% ± 6% in TNFR1−/− mice (n = 5 to 8; P <
0.05 versus WT treated with TNFa; Figure 2b). In mice
lacking TNFR2 or both TNFR1 and TNFR2, TNFa did
not significantly accelerate thrombus formation in vivo.
Without TNFa treatment, time to thrombotic vessel
occlusion was not significantly affected in either of the
TNFa receptor-deficient animals (Figure 2a).
Platelet-endothelium interaction in vivo
Next, we assessed transient interaction of platelets to the
vessel wall in vivo by intravital microscopy of vessels in
the dorsal skinfold chamber. Following systemic TNFa
treatment, interaction of injected labeled platelets with
the endothelium was slightly enhanced as indicated by a
leftward shift in platelet flow velocities and a decrease in
the median platelet velocity from 4.0 mm/second in con-
trol animals (n = 3,294 platelets, 5 different animals) to
3.7 mm/second in TNFa-treated animals (n = 3,239
platelets, 5 different animals, P <0.05 versus control ani-
mals). The fraction of rolling platelets (platelets with less
than 5% of the blood flow velocity) was only 0.1% ± 0.1%
of all analyzed injected platelets in control animals and
not significantly higher in TNFa-treated animals, in
which it was 0.4% ± 0.6% (n = 5; data not shown).
In contrast, the leftward shift in platelet velocity pattern
seen in WT mice after treatment with TNFa was much
more prominent in TNFR1−/− mice, indicating more inter-
action of platelets with the endothelium (Figure 3a). More-
over, TNFa increased the fraction of rolling platelets from
0.4% ± 0.3% in WT mice to 4.1% ± 1.0% in TNFR1−/−
mice (n = 5, P <0.01 versus WT; Figure 3b). In TNFa-
treated TNFR2−/− animals, the fraction of rolling platelets
was not significantly different compared with WT mice
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(1.1% ± 0.4%). The maximum platelet velocities in the ana-
lyzed vessels as an approximate measure of flow velocity
were not significantly different before and after TNFa
treatment or between the genotypes.
Platelet aggregation in platelet-rich plasma
To test for direct effects of TNFa on platelets, we
assessed platelet aggregation in vitro in human PRP by
using light transmission aggregometry (Born’s method).
Incubation of PRP with TNFa 5 ng/mL for different
time intervals did not affect the ability of platelets to
form aggregates upon stimulation with several com-
monly used platelet agonists - ADP (5 µmol/L), collagen
(5 to 10 µg/mL), or TRAP (5 µmol/L) - either after a
short time of incubation or after 4 hours (n = 8; results
for ADP in Figure 4a). TNFa itself did not cause platelet
Figure 1 Arteriolar thrombosis in vivo. (a) Time to thrombotic arteriolar vessel occlusion in vivo, as measured in the ferric chloride superfusion
model in the dorsal skinfold chamber in mice, was significantly accelerated when animals were treated with tumor necrosis factor alpha (TNFa)
(5 ng/mL) for 4 hours. (b) Thrombus formation after injury with ferric chloride. The arrow is pointing at a thrombus, which is spared by the
fluorescein-labeled plasma and almost occluding the vessel. *Significantly different versus sham-treated animals at P <0.05 (n = 8 to 10).
Figure 2 Tumor necrosis factor alpha (TNFa)-induced arteriolar thrombosis in vivo is increased in TNFR1-deficient mice. (a) Thrombotic
arteriolar vessel occlusion in vivo was most accelerated with TNFa (5 ng/mL, 4 hours) in TNFR1-deficient mice. In mice lacking TNFR2 only or
both TNF receptor subtypes, TNFa did not significantly affect arteriolar thrombosis. (b) In TNFR1−/− mice, the relative acceleration of arteriolar
thrombus formation by TNFa was significantly stronger compared with wild-type mice. *Significantly different versus respective sham-treated
animals at P <0.05 (n = 5 to 10). #Significantly different versus wild-type at P <0.05 (n = 5). TNFa, tumor necrosis factor alpha; TNFR1, tumor
necrosis factor alpha receptor subtype 1; TNFR2, tumor necrosis factor alpha receptor subtype 2.
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aggregation either. Also, the addition of supernatant of
TNFa-treated endothelial cells (with or without siRNA
knockdown of TNFR1 or TNFR2) to PRP had no influ-
ence on platelet aggregation (n = 4; Figure 4b).
To check whether direct activation of platelets is
responsible for prothrombotic TNFa effects in TNFR1−/−
mice, we performed platelet aggregation studies ex vivo
in PRP from TNFR1−/− mice. Like in human PRP, plate-
lets from these animals showed no differences in the abil-
ity to aggregate with or without prior TNFa incubation
(5 ng/mL) to different stimuli, including ADP and col-
lagen, at different stimulation times (n = 5; Figure 4c).
Figure 3 Tumor necrosis factor alpha (TNFa) increases platelet-endothelium interaction and platelet rolling in vivo in TNFR1-deficient
mice. (a) in vivo platelet-endothelium interaction as analyzed by intravital microscopy in the dorsal skinfold chamber was greatly enhanced in
TNFR1−/− mice pretreated with TNFa (5 ng/mL, 4 hours) compared with wild-type (WT) or TNFR2−/− mice treated likewise, as indicated by a
leftward shift in platelet velocity distribution pattern in the frequency histogram of analyzed platelet velocities. (b) When rolling platelets
(defined as platelets with velocity of less than 5% of maximum velocity) were quantified after TNFa treatment, the fraction related to all
analyzed platelets was significantly higher in mice lacking TNFR1 compared with WT or TNFR2-deficient animals. (c) Digital records of
carboxyfluorescein-labeled platelets in arterioles with increased platelet-endothelium interaction and rolling platelets (arrow). *Significantly
different versus WT and TNFR2−/− mice at P <0.01 (n = 3 to 5). plts, platelets; TNFR1, tumor necrosis factor alpha receptor subtype 1; TNFR2,
tumor necrosis factor alpha receptor subtype 2.
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TNFa-induced prothrombotic changes in endothelial cells
in vitro
To better define the relative contribution of the endothe-
lium to TNFa-dependent prothrombotic effects, we ana-
lyzed pro- and anti-coagulant factors in primary human
endothelial cells (HUVECs) and HMECs. We first mea-
sured the release of endothelial superoxide (O2
-) upon
TNFa stimulation in HUVECs by using the cytochrome
c assay. The photometrically recorded superoxide dismu-
tase-sensitive fraction of cytochrome c reduction,
expressed as the difference in the absorbance, depicts the
production of O2
- and was 2.2 ± 0.6-fold increased after
stimulation with TNFa for half an hour in a dose of
5 ng/mL (n = 15, P <0.05 versus control; Figure 5a).
Next, we used flow cytometry to measure the adhesion
molecule p-selectin, which is described to mediate platelet
rolling on the endothelium [31]. Whereas p-selectin was
barely detectable on the surface membrane of HUVECs
either non-stimulated or stimulated with TNFa (5 ng/mL)
for only 30 minutes, it was significantly upregulated after
Figure 4 Tumor necrosis factor alpha (TNFa) does not increase platelet aggregation in platelet-rich plasma (PRP) in vitro. (a) ADP-
induced (5 μmol/L) platelet aggregation was not increased in human PRP stimulated with TNFa (5 ng/mL, 15 minutes to 4 hours) compared
with non-stimulated PRP (n = 10). (b) Addition of supernatant from TNFa (5 ng/mL, 4 hours)-stimulated human microvascular endothelial cells
(HMECs) after small interfering RNA (siRNA) knockdown of TNFR1 or TNFR2 to PRP for 90 minutes did not change platelet aggregation (n = 6).
(c) No difference in platelet aggregation was observed after incubation with TNFa (5 ng/mL, 30 minutes) in PRP from TNFR1−/− mice. The
aggregation traces are representative of five independent experiments. Ctr., control; T1-KD, tumor necrosis factor alpha receptor subtype 1
knockdown; T2-KD, tumor necrosis factor alpha receptor subtype 2 knockdown; TNFR1−/−, tumor necrosis factor alpha receptor subtype 1
knockout; WT, wild-type.
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Figure 5 Tumor necrosis factor alpha (TNFa) induces prothrombotic effects in endothelial cells in vitro. Treatment of endothelial cells
with TNFa (5 ng/mL, 4 hours) led to increased superoxide release as assessed by cytochrome c reduction (a) and upregulation of P-selectin on
the surface membrane (b) in human umbilical vein endothelial cells. Additionally, TNFa decreased thrombomodulin (c) and increased
plasminogen activator inhibitor 1 (PAI-1) (d) as measured by real-time polymerase chain reaction in human microvascular endothelial cells
(HMECs). (e) TNFa elevated tissue factor expression as well as protein on the cell surface membrane. (f) These changes resulted in significant
acceleration of blood clotting time induced by lysates of TNFa-treated HMECs. (g-j) The supernatant of TNFa (5 ng/mL, 4 hours)-treated HMECs
was used to stimulate untreated endothelial cells. This resulted in an upregulation of P-selectin after 30 minutes and prothrombotic changes in
mRNA levels of thrombomodulin, PAI-1, and tissue factor which were qualitatively similar to, but less than those achieved by direct TNFa
stimulation, indicating that autocrine factors secreted by TNFa-stimulated HMECs contribute to the prothrombotic phenotype. *Significantly
different versus control at P < 0.05 (n = 6 to 8). MFI, mean fluorescence intensity; rel. to ctr., relative to control.
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4 hours, with an increase in the mean relative fluorescence
of 50.4% ± 13.7% (P <0.05, n = 5; Figure 5b).
Thrombomodulin expression was found to be sup-
pressed by 79.8% ± 2.4% upon treatment with TNFa
5 ng/mL for 4 hours (P <0.05, n = 8; Figure 5c). Further-
more, PAI-1, one of the most potent inhibitors of fibrino-
lysis, and tissue factor (CD142), which plays a crucial role
in the activation of the extrinsic pathway of the coagula-
tion cascade, were measured by real-time PCR in
HMECs upon stimulation with TNFa for 30 minutes or
4 hours at 5 ng/mL. After 4 hours, mRNA levels of PAI-1
were more than fivefold higher compared with baseline
(fold increase 5.3 ± 0.5; P <0.05, n = 16; Figure 5d), and
both tissue factor expression and tissue factor protein on
the surface membrane of HMECs were significantly upre-
gulated after 4 hours of treatment with TNFa 5 ng/mL
(11.6 ± 2.0-fold and 3.4 ± 0.3-fold increase versus base-
line, respectively, P <0.05, n = 8 to 10; Figure 5e).
Ultimately, in an endothelial-dependent clotting assay in
whole blood, clotting time upon induction with HMEC
lysates after stimulation with TNFa (5 ng/mL for
4 hours) was accelerated from 12.5 ± 0.3 minutes to 5.5 ±
0.4 minutes (P <0.05, n = 4; Figure 5f).
Endothelium-derived mediators induce prothrombotic
molecules
To test whether endothelial cells stimulated with TNFa
secrete mediators which contribute to TNFa-dependent
prothrombotic effects, HUVECs or HMECs were incu-
bated for 30 minutes (for p-selectin) and 4 hours (for
thrombomodulin, PAI-1, and tissue factor expression)
with supernatants of cells previously stimulated with
TNFa at 5 ng/mL for 3 hours. Whereas p-selectin was
slightly but not significantly increased (n = 6; Figure 5g),
expression levels of thrombodulin were reduced by 44% ±
12% (P <0.05, n = 4; Figure 5h), and mRNA levels of
PAI-1 and tissue factor were significantly increased (3.3 ±
03-fold and 9.9 ± 0.8-fold increase versus baseline, respec-
tively, P <0.05, n = 4; Figure 5i,j).
Relative contribution of TNFR1 and TNFR2 in mediation
of TNFa-dependent prothrombotic effects in vitro
To define the relative contribution of the TNFR sub-
types to induction of single genes relevant in thrombo-
sis, knockdowns of TNFR1 and TNFR2 were performed
in HMECs and HUVECs by using siRNA. As tested by
real-time PCR and Western blot after 24 and 48 hours,
respectively, for both receptors, a knockdown of about
55% could be achieved (Figure 6j).
Whereas upregulation of p-selectin was inhibited only
by knockdown of TNFR2 (Figure 6a), TNFa-dependent
changes in thrombomodulin and PAI-1 expression were
significantly reduced by TNFR1 knockdown (Figure 6b,c).
TNFa-induced upregulation of tissue factor was signifi-
cantly reduced by knockdown of both TNFR subtypes
(Figure 6d).
Thrombomodulin suppression induced by the super-
natant of TNFa-stimulated HMECs was abolished after
TNFR2 knockdown (n = 4; Figure 6f), and p-selectin,
PAI-1, and tissue factor upregulations induced by solu-
ble mediators released upon TNFa stimulation were not
changed after knockdown of either of the TNF receptor
subtypes (n = 4; Figure 6e,g,h). Knockdown of both
TNFR1 and TNFR2 significantly inhibited endothelial-
dependent TNFa-induced acceleration of blood clotting
(P < 0.05, n = 4; Figure 6i).
Discussion
This study provides evidence of TNFa significantly
accelerating ferric chloride-induced thrombus formation
in an in vivo mouse model for arteriolar thrombosis. Its
prothrombotic effects in vivo require the endothelial
expression of TNFR2 and are more pronounced in the
absence of TNFR1. in vitro studies indicate endothelial
mechanisms to be responsible for prothrombotic TNFa
effects, including an enhanced endothelial production of
reactive oxygen species; upregulation of p-selectin, tissue
factor, and PAI-1 expression; and suppression of throm-
bomodulin. TNFa results in the release of soluble med-
iators by endothelial cells which induce prothrombotic
and suppress anticoagulant genes similar to direct
TNFa-effects, but to a lesser extent. The early occlusion
of capillary vessels might well be relevant in autoim-
mune disorders, as both endothelial cell activation and
an enhanced influx of inflammatory cells are able to
promote disease manifestations, and, in fact, microvessel
changes have been a long-standing diagnostic tool in
nailfold capillary microscopy and are well defined in
lupus nephritis.
Our findings are consistent with the previously charac-
terized direct effects of TNFa on endothelial cells, such
as the induction of pro-inflammatory cytokines, fibrin
deposition, and an increase in permeability [15-17,32].
In contrast, ex vivo platelet aggregation in our study was
not influenced either by TNFa itself or by soluble media-
tors released by endothelial cells upon stimulation with
TNFa. Of note, a weak direct activation of platelets by
TNFa has been described [33,34]; indeed, from our in
vivo results, we cannot exclude a direct effect of TNFa
on platelets. In regard to our in vivo studies, we do expli-
citly consider our results not to be conflicting with the
prior experimental evidence for antithrombotic activity
of TNFa in a short time stimulation protocol [35]. In our
model of arteriolar thrombosis, we observed a signifi-
cantly accelerated time to thrombotic vessel occlusion
upon injury 4 hours after systemic treatment with TNFa,
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Figure 6 Contribution of tumor necrosis factor (TNF) receptor subtypes to prothrombotic effects in endothelial cells in vitro. (a) TNFa
(5 ng/mL, 4 hours)-induced upregulation of P-selectin is significantly reduced after TNFR2 knockdown. Whereas TNFa-dependent prothrombotic
changes in thrombomodulin and plasminogen activator inhibitor 1 (PAI-1) expression were only reduced after TNFR1 knockdown (b, c), single
knockdown of TNFR1 and TNFR2 both significantly reduced TNFa-induced generation of tissue factor (d) and eventually acceleration of blood
clotting induced by human microvascular endothelial cell (HMEC) lysates (i). (e-h) The contribution of secreted autocrine factors (as assessed by
stimulation with the supernatant of TNFa (5 ng/mL, 4 hours)-treated HMECs) to upregulation of P-selectin, PAI-1, and tissue factor was not changed
after specific TNF receptor knockdown, while reduction of thrombomodulin was inhibited after knockdown of TNFR2. (j) Knockdown of TNFR1 (left)
and TNFR2 (right) was achieved by small interfering RNA (siRNA) and magnetofection and was confirmed on mRNA as well as protein level as
measured by real-time polymerase chain reaction and Western blot after 24 and 48 hours, respectively. *Significantly different versus respective
control at P <0.05. #Significantly different versus control-transfected cells treated with TNFa (n = 4 to 8 independent experiments). ctr., control;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MFI, mean fluorescence intensity; Neg., negative; rel. to ctr., relative to control; resp. ctr.,
respective control; TNFR1, tumor necrosis factor alpha receptor subtype 1; TNFR2, tumor necrosis factor alpha receptor subtype 2.
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and this is consistent with other studies of thrombosis in
an inflammatory milieu [36]; after 30 minutes, neither
pro- nor anti-thrombotic effects were seen, and this
could be explained by differences in the injury model as
well as in the vascular bed.
In this work, we compared arteriolar thrombus forma-
tion and platelet-endothelium interaction in mice defi-
cient in TNFR1 or TNFR2 and animals lacking both
TNFa receptor subtypes. Just as the site- and time-
dependent context of its release, the complex interplay
between TNFa receptor subtypes is pivotal in defining
the actual effect of TNFa [3]. In addition, though sharing
the same signaling pathways, responses of immune cells
differ from those of non-immune cells, which ultimately
cause organ-specific pathology in chronic inflammation
[37] and hence represent equally important targets in the
therapy of autoimmune diseases. Not only is the expres-
sion of TNFR2 highly regulated, but the stimulation of
TNFR2 encompasses the induction of endogenous
TNFa, and reverse signaling through tmTNFa that influ-
ences expression of cytokines and adhesion molecules in
the tmTNFa-bearing cell has been described [38]. In
regard to vascular biology in particular, TNFR2 seems to
be crucial for both TNFa-induced atherosclerotic lesions
in mouse models for atherosclerosis [39-41] and leuko-
cyte interaction with the endothelium [42]. Our observa-
tions indicate that TNFR2 is required to mediate the
prothrombotic effects of TNFa in vivo, whereas TNFR1
partly compensates these effects, since the prothrombotic
effect of TNFa is potentiated in TNFR1 knockout mice
when compared with WT animals. However, activation
of TNFR1 does not seem to have antithrombotic activity
itself but is merely able to attenuate the prothrombotic
effects mediated by activation of TNFR2; indeed, TNFR2
knockout mice do not show a significantly longer vessel
occlusion time than mice either not pretreated with
TNFa or lacking both TNFR subtypes.
As platelets from TNFR1-deficient mice ex vivo do not
aggregate more than WT platelets, TNFR2-mediated
prothrombotic effects in vivo are likely not to rely on
direct effects on platelets. Hence, we investigated TNFa-
dependent changes in the expression of prothrombotic
molecules in endothelial cells in vitro after siRNA knock-
down of TNFR1 or TNFR2. According to the conclusion
from the in vivo experiments, in which prothrombotic
effects required TNFR2 and were more pronounced in
the absence of TNFR1, mediators of a procoagulant
milieu were expected to be less inducible by TNFa in the
TNFR2 knockdown cells. This could be confirmed for
p-selectin; however, TNFa-dependent induction of PAI-1
and suppression of thrombomodulin seemingly depended
predominantly on TNFR1, while both TNFR subtypes
were required for the upregulation of tissue factor and
endothelial-dependent clotting. Interestingly, normal
expression of TNFR2 was also necessary for the secretion
of soluble mediators causing the suppression of thrombo-
modulin. Discrepancies to in vivo experiments can be
explained by the incomplete receptor knockdown in
vitro, which implicates a persistent interplay between the
receptor subtypes. In addition, the analysis of single tar-
get genes in the endothelium certainly does not entirely
reflect the complex setting of inflammation and coagula-
tion in vivo.
With respect to clinical implications, the relevance of
experimental results to most clinical conditions in humans
is not clear as the majority of studies have been done
in genetically deficient mice. However, anticytokine
approaches with soluble receptor antagonists and mono-
clonal antibodies have become a mainstay in therapy of
RA and other chronic inflammatory diseases. So far, there
is no evidence of an increase in thrombotic events in
patients treated with TNFa antagonists [43]. In this con-
text, the finding that prothrombotic TNFa effects are
mediated by TNFR2 is intriguing as deterioration of
microcirculation in inflammation could well be relevant
with respect to drug delivery, particularly prone to be
compromised at the sites defined as therapeutic targets.
Maintenance or reconstitution of an unhampered blood
flow should be attained particularly well by a more selec-
tive therapeutic approach consisting of a TNFR2-specific
antagonist. The implementation of TNFR2-specific
antagonists has already been advocated because the highly
regulated receptor subtype TNFR2 mediates tissue damage
in chronic inflammation. A selective blockade of TNFR2
would also allow downregulation of excessive TNFa
signaling in uncontrolled inflammatory processes while
leaving unaffected beneficial TNFa effects. In addition,
amplification of TNFR1 responses by ligand passing and
reverse signaling through tmTNFa would both be abol-
ished by antagonizing TNFR2. Still, with regard to the
improvement of therapeutic strategies, we consider the
observation of soluble, endothelium-derived mediators to
be very important as they presumably allow a local ampli-
fication of prothrombotic responses in inflammation.
Conclusions
We hereby provide evidence for prothrombotic effects of
the inflammatory cytokine TNFa. In our in vivo model of
arteriolar thrombosis, both prothrombotic effects and
increased platelet rolling are mediated through endothelial
TNFR subtype 2 and partly compensated for by TNFR
subtype 1. In vitro, both TNFa itself and a TNFa-induced
release of soluble mediators led to an induction of pro-
thrombotic and a suppression of anticoagulant molecules
in human endothelial cells, resulting in an accelerated clot-
ting time in endothelial cell-based assays. Assuming that
the occlusion of capillary vessels in autoimmune disorders
is relevant well beyond mere thrombosis, we argue in
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favor of a more selective therapeutic approach in anticyto-
kine therapy based on TNFR2-specific antagonists.
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